Literature DB >> 24502620

Circulating purine compounds, uric acid, and xanthine oxidase/dehydrogenase relationship in essential hypertension and end stage renal disease.

Milojkovic Boban1, Gordana Kocic, Sonja Radenkovic, Radmila Pavlovic, Tatjana Cvetkovic, Marina Deljanin-Ilic, Stevan Ilic, Milojkovic D Bobana, Boris Djindjic, Dijana Stojanovic, Dusan Sokolovic, Tatjana Jevtovic-Stoimenov.   

Abstract

Purine nucleotide liberation and their metabolic rate of interconversion may be important in the development of hypertension and its renal consequences. In the present study, blood triphosphate (ATP), adenosine diphosphate (ADP), and adenosine monophosphate (AMP) breakdown pathway was evaluated in relation to uric acid concentration and xanthine dehydrogenase/xanthine oxidase (XDH/XO) in patients with essential hypertension, patients with chronic renal diseases on dialysis, and control individuals. The pattern of nucleotide catabolism was significantly shifted toward catabolic compounds, including ADP, AMP, and uric acid in patients on dialysis program. A significant fall of ATP was more expressed in a group of patients on dialysis program, compared with the control value (p<0.001), while ADP and AMP were significantly increased in both groups of patients compared with control healthy individuals (p<0.001), together with their final degradation product, uric acid (p<0.001). The index of ATP/ADP and ATP/uric acid showed gradual significant fall in both the groups, compared with the control value (p<0.001), near five times in a group on dialysis. Total XOD was up-regulated significantly in a group with essential hypertension, more than in a group on dialysis. The activity of XO, which dominantly contributes reactive oxygen species (ROS) production, significantly increased in dialysis group, more than in a group with essential hypertension. In conclusion, the examination of the role of circulating purine nucleotides and uric acid in pathogenesis of hypertension and possible development of renal disease, together with XO role in ROS production, may help in modulating their liberation and ROS production in slowing progression from hypertension to renal failure.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24502620     DOI: 10.3109/0886022X.2014.882240

Source DB:  PubMed          Journal:  Ren Fail        ISSN: 0886-022X            Impact factor:   2.606


  13 in total

Review 1.  Diabetic Kidney Disease: From Pathogenesis to Novel Treatment Possibilities.

Authors:  Ara Aboolian; Sofia Urner; Michael Roden; Jay Chandra Jha; Karin Jandeleit-Dahm
Journal:  Handb Exp Pharmacol       Date:  2022

2.  A novel mechanism of vitamin D anti-inflammatory/antioxidative potential in type 2 diabetic patients on metformin therapy.

Authors:  Milena Cojic; Radivoj Kocic; Aleksandra Klisic; Ljiljana Cvejanov-Kezunovic; Nebojsa Kavaric; Gordana Kocic
Journal:  Arch Med Sci       Date:  2020-02-04       Impact factor: 3.318

3.  Phosphoribosyl Pyrophosphate Amidotransferase Promotes the Progression of Thyroid Cancer via Regulating Pyruvate Kinase M2.

Authors:  Bing Liu; Meiyue Song; Huadong Qin; Bin Zhang; Yao Liu; Yu Sun; Yanfei Ma; Tiefeng Shi
Journal:  Onco Targets Ther       Date:  2020-08-03       Impact factor: 4.147

4.  Xanthine oxidase and uric acid as independent predictors of albuminuria in patients with diabetes mellitus type 2.

Authors:  Aleksandra Klisic; Gordana Kocic; Nebojsa Kavaric; Milovan Jovanovic; Verica Stanisic; Ana Ninic
Journal:  Clin Exp Med       Date:  2017-12-06       Impact factor: 3.984

5.  Non-purine selective xanthine oxidase inhibitor ameliorates glomerular endothelial injury in InsAkita diabetic mice.

Authors:  Seiji Itano; Hiroyuki Kadoya; Minoru Satoh; Takashi Nakamura; Takayo Murase; Tamaki Sasaki; Yashpal S Kanwar; Naoki Kashihara
Journal:  Am J Physiol Renal Physiol       Date:  2020-09-21

6.  Xanthine oxidoreductase reference values in platelet-poor plasma and platelets in healthy volunteers.

Authors:  Elżbieta Cecerska-Heryć; Anna Jesionowska; Szupiluk Klaudyna; Siewierska Katarzyna; Mączka Dominika; Pawlak Dominika; Urbańska Marta; Barbara Dołęgowska
Journal:  Oxid Med Cell Longev       Date:  2015-01-20       Impact factor: 6.543

7.  Xanthine oxidoreductase activity is associated with serum uric acid and glycemic control in hemodialysis patients.

Authors:  Ayumi Nakatani; Shinya Nakatani; Eiji Ishimura; Takayo Murase; Takashi Nakamura; Mari Sakura; Yu Tateishi; Akihiro Tsuda; Masafumi Kurajoh; Katsuhito Mori; Masanori Emoto; Masaaki Inaba
Journal:  Sci Rep       Date:  2017-11-13       Impact factor: 4.379

8.  Local and Systemic Oxidative Stress in Balkan Endemic Nephropathy Is Not Associated with Xanthine Oxidase Activity.

Authors:  Andrej Veljković; Jovan Hadži-Đokić; Dušan Sokolović; Rade Čukuranović; Jovana Čukuranović-Kokoris; Dragoslav Bašić; Branka Đorđević; Marko Stojanović; Andrija Šmelcerović; Gordana Kocić
Journal:  Oxid Med Cell Longev       Date:  2020-08-18       Impact factor: 6.543

9.  Association between xanthine dehydrogenase tag single nucleotide polymorphisms and essential hypertension.

Authors:  Baogang Wu; Ying Hao; Jin Shi; Ning Geng; Tiejun Li; Yanli Chen; Zhaoqing Sun; Liqiang Zheng; Hong Li; Naijing Li; Xingang Zhang; Yingxian Sun
Journal:  Mol Med Rep       Date:  2015-07-29       Impact factor: 2.952

10.  Febuxostat, a novel xanthine oxidoreductase inhibitor, improves hypertension and endothelial dysfunction in spontaneously hypertensive rats.

Authors:  Takashi Shirakura; Johji Nomura; Chieko Matsui; Tsunefumi Kobayashi; Mizuho Tamura; Hiroaki Masuzaki
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-05-20       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.